Tevogen Bio Holdings Inc.

We are a clinical-stage specialty immunotherapy company that develops off-the-shelf, precision T cell therapies. Our therapies use CD8+ cytotoxic T lymphocytes (CTLs), also known as killer T cells, which are white blood cells that destroy infected, malignant, or damaged cells. These therapies are designed to treat infectious diseases, cancers, and other disorders. Our precision T cell technology, ExacTcell, is a set of processes and methodologies used to develop, enrich, and expand single human leukocyte antigen (HLA) restricted CTL therapies with proactively selected, precisely defined targets. HLA molecules are proteins important for the immune system to distinguish between "self" and "foreign" cells, and HLA types vary among individuals. ExacTcell therapies are based on carefully selected, naturally occurring CTLs that recognize targets from the body's native T cell receptor pool, differing from genetically engineered T cell therapies. The CD8+ CTLs in ExacTcell-based products target multiple and distinct antigens. These allogeneic therapeutics are pre-manufactured, ready-to-use, and intended for infusion into individuals other than the original donor.